What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce and provide access to Abbott Laboratories' financial results for the first quarter of 2026.

Where can I find the detailed Q1 2026 financial results?

The detailed Q1 2026 financial results are provided in the press release (Exhibit 99.1) that is furnished with this 8-K filing. Investors should refer to this press release for specific financial data.

What are non-GAAP financial measures and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of the company's ongoing operational performance by adjusting for unusual or unpredictable items like acquisition-related costs, restructuring actions, and certain tax adjustments.

How should investors interpret Abbott's use of non-GAAP measures?

Abbott's management believes these non-GAAP measures offer useful insights into business performance. However, the company advises investors to consider these non-GAAP measures in conjunction with, and not as a replacement for, the financial measures prepared in accordance with GAAP.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2026, to announce its financial results for the first quarter of 2026. The filing primarily directs investors to a furnished press release (Exhibit 99.1) which contains the detailed financial performance and operational updates for the period. While specific GAAP figures are not detailed in the 8-K text itself, the company emphasizes its use of non-GAAP financial measures. These adjusted figures exclude items such as acquisition-related expenses, stock-based compensation acceleration, restructuring costs, certain regulatory costs, and tax adjustments, aiming to provide a clearer view of ongoing business performance. Management believes these non-GAAP measures offer valuable insights into operational trends, complementing the standard GAAP reporting.

Key Highlights

1Abbott Laboratories (ABT) reported its Q1 2026 financial results on April 16, 2026.
2The 8-K filing references a press release (Exhibit 99.1) containing the detailed financial results.
3The company utilizes non-GAAP financial measures to present its results, alongside GAAP figures.
4Non-GAAP measures exclude specific items like acquisition expenses, stock-based compensation acceleration, and restructuring costs.
5Abbott's management uses non-GAAP measures to assess and communicate ongoing business performance.
6Investors are advised to consider non-GAAP measures in addition to, not as a substitute for, GAAP financial measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2026)

Summary

Key Highlights

Frequently Asked Questions